Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)
Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti CTLA-4 Monoclonal Antibody (Checkmate 168: CHECKpoint Pathway for nivoluMAb Clinical Trial Evaluation 168)
The purpose of this program is to provide treatment with nivolumab to subjects with Stage III or Stage IV advanced melanoma.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Exclusion Criteria:
Lutherville, Maryland 21093, United States
Buenos Aires, Buenos Aires 1019, Argentina
Buenos Aires, Buenos Aires 1431, Argentina
Capital Federal, Buenos Aires 1280, Argentina
Ciudad Autonoma de Buenos Aire, Buenos Aires 1181, Argentina
Caba, 1426, Argentina
Jd. Petropolis-Londrina, Paraná 86015, Brazil